However, we are concerned about the competitive pressures faced by the company due to prescription reimbursement issues and slow introduction of new generic products. Moreover, our apprehensions are further bolstered by factors like higher SG&A expenses, a shift towards the low-margin pharmacy business as well as gross margins reflecting a downward trend.
Based on these factors, we have lowered our estimates for fiscal 2011 and downgrade the stock to Underperform with a target price of $26.00.
WALGREEN CO (WAG): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.